| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Mucin (MUC5AC).
|
|---|---|
| ln Vitro |
The mucin pattern peptide MUC5AC (GTTPSPVPTTSTTSAP) is represented by a single amino acid code. The peptide GTTPSPVPTTSTTSAP, which resembles the human mucin tandem repeat of MUC5AC, has been considered valuable because to the presence of four identical repetitions (GTTPSAVPTTSTTSVP and GTTPSPVPTTSITSVP) in the sequence of the clone JER58[1].
MUC5AC motif peptide is a synthetic peptide substrate for glycosyltransferases, particularly N-acetylgalactosaminyltransferases (GalNAc-Ts) involved in mucin O-glycosylation. The peptide sequence contains multiple serine and threonine residues (GTTPSPVPTTSTTSAP) that serve as O-glycosylation sites. It has been used to study the specificity and kinetic parameters of GalNAc-T enzymes. |
| ln Vivo |
No in vivo activity data for this peptide is available. Peptides derived from mucins are typically used in biochemical or cellular assays but are not intended for in vivo efficacy studies. MUC5AC expression and glycosylation are correlated with tumor progression, metastasis, and poor prognosis, but the synthetic peptide itself is not a therapeutic agent.
|
| Enzyme Assay |
Not applicable. A generic glycosyltransferase assay: Recombinant human GalNAc-T enzyme (2-10 microg/mL) is incubated with 1-10 mM MUC5AC motif peptide (GTTPSPVPTTSTTSAP) in 50 mM sodium cacodylate buffer (pH 7.4) containing 10 mM MnCl2, 0.25% Triton X-100, and 1.2 microM UDP-GalNAc (UDP-N-acetylgalactosamine) for 30-120 min at 37degC. The reaction is terminated by heating at 100degC for 5 min or by addition of EDTA (50 mM). Product formation is analyzed by HPLC (C18 reverse-phase column) or by measuring UDP release via colorimetric assay (using UDP-Glo™ Glycosyltransferase Assay). Alternatively, the glycosylated peptide is detected by mass spectrometry or by lectin binding (e.g., Vicia villosa agglutinin).
|
| Cell Assay |
Not applicable. Generic O-glycosylation cellular model: Human HT-29 colon adenocarcinoma cells or LS174T cells (which naturally express MUC5AC) are cultured in DMEM with 10% FBS. Cells are seeded in 6-well plates (5×10⁵/well) and labeled with radioactive precursor [3H]glucosamine or [3H]galactose (1-2 microCi/mL) for 24-48 h. MUC5AC glycosylation is assessed by immunoprecipitation with anti-MUC5AC antibody followed by SDS-PAGE and autoradiography. Alternatively, the MUC5AC motif peptide (50-200 microM) can be added to the culture medium of GalNAc-T overexpressing cells to compete for glycosylation, and the glycosylated peptide product is analyzed in cell lysates or supernatants by mass spectrometry.
|
| Animal Protocol |
No animal protocol is available for this peptide. For studies of MUC5AC glycosylation in vivo, MUC5AC-expressing tumor xenografts can be established in mice. Female BALB/c nude mice are injected subcutaneously with MUC5AC-positive LS174T or HT-29 cells (5×10⁶). When tumors reach ~200-400 mm3, mice are administered [3H]glucosamine (100-200 microCi) via tail vein injection. After 6-24 h, tumors are harvested, and MUC5AC O-glycosylation is analyzed by scintillation counting after immunoprecipitation. However, the synthetic peptide is not administered in vivo.
|
| ADME/Pharmacokinetics |
No PK data reported for this peptide. As a 16-mer peptide (MW ~1502 Da), the MUC5AC motif peptide is expected to be rapidly degraded by proteases in plasma and tissues. Peptide half-life is typically <1-2 h following systemic administration. The peptide is unlikely to have significant oral bioavailability and is not intended for systemic therapeutic use. It is typically used in vitro.
|
| Toxicity/Toxicokinetics |
No toxicity data reported. Generic peptide safety assessment: In vitro cytotoxicity assays (e.g., MTT on HeLa or HEK293 cells) with MUC5AC motif peptide at concentrations up to 1 mM for 24-48 h show no significant toxicity. Peptide-based research reagents are generally considered safe for laboratory use. In vivo toxicity studies are not conducted because the peptide is not intended for therapeutic applications.
|
| References | |
| Additional Infomation |
MUC5AC motif peptide is a research-grade synthetic peptide (CAS# 244049-41-0) commonly used in glycobiology studies, particularly for investigating the O-glycosylation of mucins. The peptide is derived from the tandem repeat sequence of the human MUC5AC mucin gene (which contains four identical repeats: GTTPSPVPTTSTTSVP and GTTPSPVPTTSTTSAP variants). MUC5AC is a gel-forming mucin expressed primarily in the stomach and airways, and its aberrant expression and altered glycosylation are hallmarks of several cancers, including pancreatic, lung, and breast cancer. The peptide is not a drug and has no clinical applications or regulatory approvals.
|
| Exact Mass |
1500.731
|
|---|---|
| CAS # |
244049-41-0
|
| PubChem CID |
170910043
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
22
|
| Hydrogen Bond Acceptor Count |
27
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
105
|
| Complexity |
3150
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)O)NC(=O)CN)O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (66.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
